Collaborations

Juvaris collaborates with RNA-based gene-inhibition technology company

Published in Vaccine Weekly, June 9th, 2004

Juvaris BioTherapeutics, Inc., and SomaGenics, Inc., both private biotechnology companies, announced that they have entered into a collaboration to develop products combining their technologies.

This approach combines the RNA-based gene inhibition technology of SomaGenics with the immunomodulatory and vaccine technology under development by Juvaris BioTherapeutics. The effort is directed towards the development of novel methods for immediate inhibition of pathogenesis, stimulation of innate immunity, and the development of specific immunity to disease-related antigens.

The initial focus of this collaboration is a novel immune stimulant and specific...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (2004-06-09)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry